ATE253912T1 - Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca - Google Patents

Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Info

Publication number
ATE253912T1
ATE253912T1 AT01927298T AT01927298T ATE253912T1 AT E253912 T1 ATE253912 T1 AT E253912T1 AT 01927298 T AT01927298 T AT 01927298T AT 01927298 T AT01927298 T AT 01927298T AT E253912 T1 ATE253912 T1 AT E253912T1
Authority
AT
Austria
Prior art keywords
medication
producing
treatment
receptor agonists
acetylcholine receptor
Prior art date
Application number
AT01927298T
Other languages
English (en)
Inventor
Benjamin R Yerxa
Ward M Peterson
Mathew Cowlen
Original Assignee
Inspire Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals filed Critical Inspire Pharmaceuticals
Application granted granted Critical
Publication of ATE253912T1 publication Critical patent/ATE253912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT01927298T 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca ATE253912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
ATE253912T1 true ATE253912T1 (de) 2003-11-15

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927298T ATE253912T1 (de) 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Country Status (8)

Country Link
US (1) US6277855B1 (de)
EP (1) EP1214062B1 (de)
JP (1) JP2003531168A (de)
AR (1) AR028026A1 (de)
AT (1) ATE253912T1 (de)
AU (1) AU2001253765A1 (de)
DE (1) DE60101201D1 (de)
WO (1) WO2001080844A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
AU2003258041A1 (en) * 2002-08-02 2004-02-23 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
PT1565055E (pt) * 2002-11-08 2013-09-16 Mclean Hospital Corp Compostos para o tratamento da dependência e da privação de tabaco
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
WO2004058160A2 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
WO2005060984A1 (en) * 2003-12-12 2005-07-07 Yee Richard W Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US20070053964A1 (en) * 2004-05-21 2007-03-08 Akiharu Isowaki Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
EP1752456B1 (de) * 2004-06-03 2015-08-26 Senju Pharmaceutical Co., Ltd. Eine Amidverbindung enthaltendes Arzneimittel zur Wiederherstellung des Sehvermögens der Hornhaut
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
KR20080031430A (ko) * 2005-07-26 2008-04-08 센주 세이야꾸 가부시키가이샤 경피적으로 흡수가능한 안과용 제제
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
CA2740029C (en) * 2008-05-16 2016-12-20 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
AU2009303545A1 (en) * 2008-10-14 2010-04-22 Psychogenics, Inc Nicotinic acetylcholine receptor ligands and the uses thereof
EA201100896A1 (ru) * 2009-02-11 2012-01-30 ХЕГЛУНД а.с. Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
DK2665741T3 (en) * 2011-01-10 2019-04-29 Invion Inc APPLICATION OF BETA-ADRENERGE INVERSE AGONISTS FOR SMOKE CLEANING
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9931423B2 (en) 2011-08-26 2018-04-03 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
US9265956B2 (en) 2013-03-08 2016-02-23 Oculeve, Inc. Devices and methods for treating dry eye in animals
EP2967817B1 (de) 2013-03-12 2021-03-10 Oculeve, Inc. Implantateinführungsvorrichtungen und -systeme
CN108744272A (zh) 2013-04-19 2018-11-06 奥库利维公司 鼻刺激装置和方法
RU2698711C2 (ru) 2014-02-25 2019-08-29 Окулив, Инк. Составы полимеров для носослёзной стимуляции
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
EP3673952A1 (de) 2014-07-25 2020-07-01 Oculeve, Inc. Stimulationsmuster zur behandlung von trockenen augen
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
KR20170074926A (ko) 2014-10-22 2017-06-30 오큘레브, 인크. 안구 건조증을 치료하기 위한 자극 장치 및 방법
AU2015335772B2 (en) 2014-10-22 2020-07-09 Oculeve, Inc. Contact lens for increasing tear production
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
JP2017533917A (ja) * 2014-11-05 2017-11-16 ティッシュテック，インク． 神経成長および再生を促進するための組成物および方法
JP7030516B2 (ja) 2014-12-31 2022-03-07 マイクロオプティクス インコーポレイテッド 緑内障治療装置および方法
CN107864623A (zh) * 2015-05-21 2018-03-30 摩纳哥奥夫塔尔米斯公司 作为渗透压保护剂的硫辛酸和牛磺酸的组合
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
JP6892693B2 (ja) 2015-09-30 2021-06-23 マイクロオプティクス インコーポレイテッド ドライアイ治療装置および方法
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
NZ746468A (en) * 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions
WO2017178897A2 (en) 2016-04-12 2017-10-19 Arturo Solis Herrera Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
EP3547898A4 (de) 2016-12-02 2020-07-08 Oculeve, Inc. Vorrichtung und verfahren zur vorhersage von trockenem auge und behandlungsempfehlung
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
JP2024517459A (ja) * 2021-05-07 2024-04-22 オイスター ポイント ファーマ インコーポレイテッド ベクター及びニコチン作動薬の併用療法
TW202317111A (zh) * 2021-07-07 2023-05-01 坎培拉大學 治療及抑制方法
DE102023208057A1 (de) 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
EP0659078B1 (de) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
WO2001080844A3 (en) 2002-03-28
EP1214062A2 (de) 2002-06-19
DE60101201D1 (de) 2003-12-18
WO2001080844A2 (en) 2001-11-01
AR028026A1 (es) 2003-04-23
US6277855B1 (en) 2001-08-21
AU2001253765A1 (en) 2001-11-07
JP2003531168A (ja) 2003-10-21
EP1214062B1 (de) 2003-11-12

Similar Documents

Publication Publication Date Title
DE60101201D1 (de) Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
ATE361058T1 (de) Tablette und verfahren zur herstellung derselben
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60139256D1 (de) Verfahren und vorrichtung zur herstellung von flüssigen verabreichungsformen
EP1294410A4 (de) Verfahren und zusammensetzung zum reinigen von medizinischen geräten
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
CY2012032I1 (el) Ενωσεις 1,2-διυδροπυριδινης, διεργασια για την παρασκευη των ιδιων και χρηση εξ αυτων
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
EE200200470A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE59912246D1 (de) Ferroelektrischer transistor und verfahren zu dessen herstellung
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
EE200200697A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
DE50007390D1 (de) Doppel-gate-mosfet-transistor und verfahren zu seiner herstellung
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties